Ipsen S.A. (IPSEF)
OTCMKTS
· Delayed Price · Currency is USD
120.55
-3.86 (-3.10%)
At close: Feb 7, 2025
Ipsen Revenue
In the year 2024, Ipsen had annual revenue of 3.57B EUR with 8.11% growth. Ipsen had revenue of 1.82B in the half year ending December 31, 2024, with 9.90% growth.
Revenue
3.57B EUR
Revenue Growth
+8.93%
P/S Ratio
n/a
Revenue / Employee
667.13K EUR
Employees
5,358
Market Cap
9.78B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.57B | 268.10M | 8.11% |
| Dec 31, 2023 | 3.31B | 150.00M | 4.75% |
| Dec 31, 2022 | 3.16B | 407.80M | 14.84% |
| Dec 31, 2021 | 2.75B | 62.40M | 2.32% |
| Dec 31, 2020 | 2.69B | -6.60M | -0.25% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| BioStem Technologies | 210.49M |
Ipsen News
- 27 days ago - Ipsen S.A. 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 27 days ago - Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Ipsen S.A. Non-GAAP EPS of €10.27, revenue of €3.4B; initiates FY25 outlook - Seeking Alpha
- 3 months ago - Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions - Seeking Alpha
- 5 months ago - Ipsen S.A. reports Q3 results; raises FY24 guidance - Seeking Alpha
- 5 months ago - Eton Pharmaceuticals to buy Increlex product from Ipsen - Seeking Alpha
- 6 months ago - Ipsen's Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease - Benzinga
- 6 months ago - Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade - Benzinga